Literature DB >> 31098822

Comprehensive registry of esophageal cancer in Japan, 2012.

Yuji Tachimori1, Soji Ozawa2, Hodaka Numasaki3, Ryu Ishihara4, Hisahiro Matsubara5, Kei Muro6, Tsuneo Oyama7, Yasushi Toh8, Harushi Udagawa9, Takashi Uno10.   

Abstract

Entities:  

Year:  2019        PMID: 31098822      PMCID: PMC6592979          DOI: 10.1007/s10388-019-00674-z

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


× No keyword cloud information.

Preface 2012

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2012, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with a HASH function is used for anonymity in an unlinkable fashion. We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2012. Japanese Classification of Esophageal Cancer 10th [1] and UICC TNM Classification 7th [2] were used for cancer staging according to the subjected year. A total of 8003 cases were registered from 316 institutions in Japan. Tumor locations were cervical: 4.6%, upper thoracic: 12.8%, middle thoracic: 47.9%, lower thoracic: 26.1% and EG junction: 7.6%. Superficial carcinomas (Tis, T1a, T1b) were 38.2%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 89.5% and 6.0%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 84.4, 32.4, 24.9, and 55.6%, respectively. The endoscopic submucosal dissection accounted for 84.9% of endoscopic resection. Esophagectomy was performed in 4722 cases. Concerning the approach used for esophagectomy, 36.0% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.52% and the hospital mortality was 2.35%. The 5-year survival rate of patients with pStage IV in UICC classification (including patients with supraclavicular node metastasis) was better than that of patients with pStage IVb in JES classification (not including patients with supraclavicular node metastasis). We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2012 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Contents

Clinical factors of esophageal cancer patients treated in 2012 Institution-registered cases in 2012 Patient background Table Age and gender
Table 1

Age and gender

AgeMaleFemaleCases (%)
≤ 29314 (0.0%)
30-39161430 (0.4%)
40-4916358221 (2.8%)
50-5910281881216 (15.2%)
60-6928144533267 (40.8%)
70-7922743712645 (33.1%)
80-89476118594 (7.4%)
90≤18826 (0.3%)
Total679212118003
Table Primary treatment
Table 2

Primary treatment

TreatmentsCases (%)
Surgery4798 (60.0%)
 Esophagectomy4722 (59.0%)
 Palliative surgery76 (1.0%)
Chemotherapy/radiotherapy1794 (22.4%)
Endoscopic treatment1407 (17.6%)
Total7999
Table Tumor location
Table 3

Tumor location

Location of tumorEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
Cervical41 (2.9%)152 (3.2%)3 (3.9%)174 (9.7%)370 (4.6%)
Upper thoracic122 (8.7%)581 (12.3%)18 (23.7%)302 (16.8%)1023 (12.8%)
Middle thoracic819 (58.2%)2151 (45.6%)37 (48.7%)825 (46.0%)3832 (47.9%)
Lower thoracic335 (23.8%)1344 (28.5%)14 (18.4%)392 (21.9%)2085 (26.1%)
EG58 (4.1%)356 (7.5%)2 (2.6%)39 (2.2%)455 (5.7%)
E = G14 (1.0%)56 (1.2%)1 (1.3%)10 (0.6%)81 (1.0%)
GE4 (0.3%)59 (1.2%)1 (1.3%)7 (0.4%)71 (0.9%)
Unknown14 (1.0%)23 (0.5%)45 (2.5%)82 (1.0%)
Total140747227617947999

E esophageal, G gastric

Table Histologic types of biopsy specimens
Table 4

Histologic types of biopsy specimens

Histologic typesCases (%)
Squamous cell carcinoma7162 (89.5%)
 Squamous cell carcinoma5130 (64.1%)
 Well differentiated440 (5.5%)
 Moderately differentiated1177 (14.7%)
 Poorly differentiated415 (5.2%)
Adenocarcinoma358 (4.5%)
Barrett’s adenocarcinoma119 (1.5%)
Adenosquamous carcinoma15 (0.2%)
Mucoepidermoid carcinoma6 (0.1%)
Basaloid carcinoma41 (0.5%)
Neuroendocrine cell tumor24 (0.3%)
Undifferentiated carcinoma12 (0.2%)
Sarcoma79 (1.0%)
Malignant melanoma1 (0.0%)
Carcinosarcoma19 (0.2%)
GIST14 (0.2%)
Other tumors2 (0.0%)
Unknown147 (1.8%)
Total7999
Table Depth of tumor invasion, cT (UICC TNM 7th)
Table 5

Depth of tumor invasion, cT (UICC TNM 7th)

cTCases (%)
cTX100 (1.3%)
cT014 (0.2%)
cTis216 (2.7%)
cT1a1264 (15.8%)
cT1b1575 (19.7%)
cT21004 (12.6%)
cT32843 (35.5%)
cT4a395 (4.9%)
cT4b538 (6.7%)
Unknown50 (0.6%)
Total7999
Table Lymph node metastasis, cN (UICC TNM 7th)
Table 6

Lymph node metastasis, cN (UICC TNM 7th)

cNCases (%)
cNX170 (2.1%)
cN03796 (47.5%)
cN12020 (25.3%)
cN21335 (16.7%)
cN3519 (6.5%)
Unknown159 (2.0%)
Total7999
Table Distant metastasis, cM (UICC TNM 7th)
Table 7

Distant metastasis, cM (UICC TNM 7th)

cMCases (%)
cM07214 (90.2%)
cM1740 (9.3%)
Unknown45 (0.6%)
Total7999
Table Clinical stage (UICC TNM 7th)
Table 8

Clinical stage (UICC TNM 7th)

Clinical StageEndoscopic treatment(%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
Stage 0254 (18.1%)104 (2.2%)2 (2.6%)54 (3.0%)414 (5.2%)
Stage IA981 (69.7%)1117 (23.7%)1 (1.3%)201 (11.2%)2300 (28.8%)
Stage IB6 (0.4%)393 (8.3%)50 (2.8%)449 (5.6%)
Stage IIA5 (0.4%)499 (10.6%)6 (7.9%)79 (4.4%)589 (7.4%)
Stage IIB3 (0.2%)458 (9.7%)88 (4.9%)549 (6.9%)
Stage IIIA9 (0.6%)951 (20.1%)14 (18.4%)210 (11.7%)1184 (14.8%)
Stage IIIB10 (0.7%)510 (10.8%)6 (7.9%)117 (6.5%)643 (8.0%)
Stage IIIC20 (1.4%)384 (8.1%)26 (34.2%)418 (23.3%)848 (10.6%)
Stage IV36 (2.6%)183 (3.9%)16 (21.1%)505 (28.1%)740 (9.3%)
Unknown83 (5.9%)123 (2.6%)5 (6.6%)72 (4.0%)283 (3.5%)
Total140747227617947999
Results of endoscopically treated patients in 2012 Table Details of endoscopic treatment for curative intent
Table 9

Details of endoscopic treatment for curative intent

Treatment detailsCases (%)
EMR185 (14.2%)
EMR + YAG laser6 (0.5%)
EMR + MCT/RFA1 (0.1%)
ESD1064 (81.9%)
ESD + EMR2 (0.2%)
ESD + PDT8 (0.6%)
ESD + YAG laser8 (0.6%)
PDT3 (0.2%)
YAG laser22 (1.7%)
Total1299

EMR endoscopic mucosal resection, PDT photodynamic therapy, YAG yttrium aluminum garnet, MCT microwave coagulation therapy, ESD endoscopic submucosal dissection

Table Complications of EMR/ESD
Table 10

Complications of EMR/ESD

Complications of EMR/ESDCases (%)
None1206 (94.7%)
Perforation20 (1.6%)
Bleeding1 (0.1%)
Stenosis35 (2.7%)
Others5 (0.4%)
Unknown7 (0.5%)
Total1274
Table Pathological depth of tumor invasion of EMR/ESD specimens
Table 11

Pathological depth of tumor invasion of EMR/ESD specimens

Pathological depth of tumor invasionCases (%)
pTX6 (0.5%)
pT010 (0.8%)
pTis234 (18.4%)
pT1a873 (68.5%)
pT1b140 (11.0%)
pT22 (0.2%)
Unknown9 (0.7%)
Total1274
Figure Survival of patients treated with EMR/ESD
Fig. 1

Survival of patients treated with EMR/ESD

Figure Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion, pT (UICC TNM 7th)
Fig. 2

Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion, pT (UICC TNM 7th)

Figure Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion
Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

Results in patients treated with chemotherapy and/or radiotherapy in 2012 Table Dose of irradiation (non-surgically treated cases)
Table 12

Dose of irradiation (non-surgically treated cases)

Dose of irradiation (Gy)DefinitivePalliative (%)Recurrence (%)Others (%)Unknown (%)Total (%)
Radiation alone (%)Chemoradiotherapy (%)
− 297 (3.2%)14 (1.5%)14 (4.5%)1 (3.3%)36 (2.4%)
30–393 (1.4%)13 (1.4%)46 (14.7%)1 (20.0%)5 (16.7%)1 (2.5%)69 (4.6%)
40–494 (1.9%)36 (4.0%)63 (20.1%)1 (20.0%)7 (23.3%)1 (2.5%)112 (7.4%)
50–5935 (16.2%)192 (21.2%)76 (24.3%)8 (26.7%)10 (25.0%)321 (21.3%)
60–69127 (58.8%)546 (60.4%)103 (32.9%)3 (60.0%)7 (23.3%)27 (67.5%)813 (53.9%)
70-7 (3.2%)30 (3.3%)4 (1.3%)(0.0%)41 (2.2%)
Unknown33 (15.3%)73 (8.1%)7 (2.2%)2 (6.7%)1 (2.5%)116 (7.7%)
Total216904313530401508
Median (min–max)60.0 (2.0–139.0)60.0 (8.0–104.4)50.0 (2.0–126.0)60.0 (30.0–63.0)50.0 (4.5–63.0)60.0 (30.0–66.0)60.0 (2.0–139.0)
Table Dose of irradiation (surgically treated cases)
Table 13

Dose of irradiation (surgically treated cases)

Dose of irradiation (Gy)Preoperative irradiation (%)Postoperative irradiation (%)
− 293 (1.0%)1 (1.8%)
30–3986 (28.6%)3 (5.4%)
40–49166 (55.1%)9 (16.1%)
50–5910 (3.3%)17 (30.4%)
60–6923 (7.6%)23 (41.1%)
70–
Unknown13 (4.3%)3 (5.4%)
Total30156
Median (min–max)40.0 (3.0–66.6)50.5 (16.0–66.0)
Figure Survival of patients treated with chemotherapy and/or radiotherapy
Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Figure Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)
Fig. 5

Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)

Figure Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)
Fig. 6

Survival of patients treated with radiotherapy alone according to clinical stage (UICC TNM 7th)

Results in patients who underwent esophagectomy in 2012 Table Treatment modalities of esophagectomy
Table 14

Treatment modalities of esophagectomy

TreatmentsCases (%)
Esophagectomy1792 (38.0%)
Esophagectomy + endoscopic treatment123 (2.6%)
Esophagectomy + chemoradiotherapy806 (17.1%)
 Concurrent chemoradiotherapy557 (11.8%)
 Other249 (5.3%)
Esophagectomy + chemoradiotherapy + endoscopic treatment24 (0.5%)
Esophagectomy + chemoradiotherapy + other treatment1 (0.0%)
Esophagectomy + radiotherapy67 (1.4%)
 Preoperative15 (0.3%)
 Postoperative23 (0.5%)
 Recurrence4 (0.1%)
 Other25 (0.5%)
Esophagectomy + chemotherapy1886 (39.9%)
Preoperative1473 (31.2%)
Postoperative253 (5.4%)
Recurrence52 (1.1%)
Other108 (2.3%)
Esophagectomy + chemotherapy + endoscopic treatment21 (0.4%)
Esophagectomy + chemotherapy + other treatment1 (0.0%)
Esophagectomy + other treatment1 (0.0%)
Total4722
Table Tumor location
Table 15

Tumor location

LocationsCases (%)
Cervical152 (3.2%)
Upper thoracic581 (12.3%)
Middle thoracic2151 (45.6%)
Lower thoracic1344 (28.5%)
E > G356 (7.5%)
E = G56 (1.2%)
G > E59 (1.2%)
Unknown23 (0.5%)
Total lesions4722
Table Approaches to tumor resection
Table 16

Approaches to tumor resection

ApproachesCases (%)
Cervical approach83 (1.8%)
Right thoracic4070 (86.2%)
Left thoracic81 (1.7%)
Left thoracoabdominal80 (1.7%)
Abdominal173 (3.7%)
Transhiatal thoracic esophagectomy59 (1.2%)
Transhiatal lower esophagectomy115 (2.4%)
Sternotomy9 (0.2%)
Others25 (0.5%)
Unknown27 (0.6%)
Total4722

Thoracic includes thoracotomy and thoracoscopic

Abdominal includes laparotomy and laparoscopic

Table Video-assisted surgery
Table 17

Video-assisted surgery

Video-assisted surgeryCases (%)
None2623 (55.5%)
Thoracoscopy983 (20.8%)
Thoracoscopy + laparoscopy712 (15.1%)
Thoracoscopy + laparoscopy + mediastinoscopy3 (0.1%)
Thoracoscopy + laparoscopy + other1 (0.0%)
Thoracoscopy + mediastinoscopy3 (0.1%)
Thoracoscopy + other2 (0.0%)
Laparoscopy218 (4.6%)
Laparoscopy + mediastinoscopy11 (0.2%)
Laparoscopy + mediastinoscopy + other13 (0.3%)
Mediastinoscopy41 (0.9%)
Others107 (2.3%)
Unknown5 (0.1%)
Total4722
Table Fields of lymph node dissection according to the location of the tumor
Table 18

Fields of lymph node dissection according to the location of the tumor

Field of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracicE > GE = GG > EUnknownTotal
None19 (12.5%)27 (4.6%)81 (3.8%)39 (2.9%)17 (4.8%)3 (5.4%)11 (4.3%)188 (4.0%)
C40 (26.3%)8 (1.4%)8 (0.4%)5 (0.4%)(0.0%)61 (1.3%)
C + UM16 (10.5%)3 (0.5%)3 (0.1%)2 (0.1%)1 (1.8%)126 (0.6%)
C + UM + MLM11 (7.2%)25 (4.3%)43 (2.0%)18 (1.3%)1 (0.3%)98 (2.1%)
C + UM + MLM + A45 (29.6%)369 (63.5%)1103 (51.3%)506 (37.6%)39 (11.0%)3 (5.4%)1 (1.7%)6 (26.1%)2072 (43.9%)
C + UM + MLM + A + OT1 (0.1%)1 (0.0%)
C + UM + A3 (2.0%)5 (0.9%)1 (0.0%)2 (0.1%)11 (0.2%)
C + MLM1(0.0%)1 (0.1%)2 (0.0%)
C + MLM + A4 (0.3%)7 (0.3%)5 (0.4%)1 (0.3%)17 (0.4%)
C + A2 (1.3%)4 (0.2%)1 (0.1%)7 (0.1%)
UM5 (0.2%)2 (0.1%)3 (0.8%)10 (0.2%)
UM + MLM1 (0.7%)11 (1.9%)33 (1.5%)14 (1.0%)4 (1.1%)2 (8.7%)

65

(1.4%)

UM + MLM + A10 (6.6%)110 (18.9%)768 (35.7%)595 (44.3%)115 (32.3%)11 (19.6%)7 (11.9%)8 (34.8%)1624 (34.4%)
UM + MLM + A + OT1 (0.1%)1 (0.0%)
UM + A7 (0.3%)3 (0.2%)1 (0.3%)11 (0.2%)
MLM1 (0.2%)9 (0.4%)7 (0.5%)4 (1.1%)21 (0.4%)
MLM + A8 (1.4%)45 (2.1%)105 (7.8%)129 (36.2%)26 (46.4%)27 (45.8%)2 (8.7%)342 (7.2%)
A1 (0.7%)3 (0.5%)21 (1.0%)29 (2.2%)40 (11.2%)9 (16.1%)23 (39.0%)1 (4.3%)127 (2.7%)
A + OT1 (0.1%)1 (0.0%)
Unknown4 (2.6%)6 (1.0%)11 (0.5%)9 (0.7%)2 (0.6%)3 (5.4%)2 (8.7%)37 (0.8%)
Total15258121511344356564722

C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes

Table Reconstruction route
Table 19

Reconstruction route

RouteCases (%)
None66 (1.4%)
Subcutaneous414 (8.8%)
Retrosternal1799 (38.1%)
Posterior mediastinal519 (11.0%)
Intrathoracic1794 (38.0%)
Cervical46 (1.0%)
Others49 (1.0%)
Unknown35 (0.7%)
Total4722
Table Organs used for reconstruction
Table 20

Organs used for reconstruction

Organs used for reconstructionCases (%)
None62 (1.3%)
Whole stomach49 (1.0%)
Gastric tube4057 (85.0%)
Jejunum286 (6.0%)
Free jejunum94 (2.0%)
Colon157 (3.3%)
Free colon12 (0.3%)
Others24 (0.5%)
Unknown33 (0.7%)
Total organs4774
Total cases4722
Table Histological classification
Table 21

Histological classification

Histological classificationCases (%)
Squamous cell carcinoma3990 (84.5%)
 Squamous cell carcinoma973 (20.6%)
 Well differentiated713 (15.1%)
 Moderately differentiated1788 (37.9%)
 Poorly differentiated516 (10.9%)
Adenocarcinoma239 (5.1%)
Barrett’s adenocarcinoma109 (2.3%)
Adenosquamous carcinoma30 (0.6%)
Mucoepidermoid carcinoma5 (0.1%)
Adenoid cystic carcinoma3 (0.1%)
Basaloid carcinoma81 (1.7%)
Neuroendocrine cell tumor21 (0.4%)
Undifferentiated carcinoma12 (0.3%)
Other carcinoma6 (0.1%)
Carcinosarcoma36 (0.8%)
Malignant melanoma11 (0.2%)
GIST1 (0.0%)
Other46 (1.0%)
Unknown132 (2.8%)
Total4722
Table Depth of tumor invasion, pT (JES 10th)
Table 22

Pathological depth of tumor invasion, pT (JES 10th)

Pathological depth of tumor invasionCases (%)
pTX71 (1.5%)
pT0156 (3.3%)
pTis33 (0.7%)
pT1a503 (10.7%)
pT1b1256 (26.6%)
pT2570 (12.1%)
pT31824 (38.6%)
pT420 (0.4%)
pT4a147 (3.1%)
pT4b103 (2.2%)
Unknown39 (0.8%)
Total4722
Table Pathological grading of lymph node metastasis, pN (JES 10th)
Table 23

Pathological grading of lymph node metastasis, pN (JES 10th)

Lymph node metastasisCases (%)
pN02237 (47.4%)
pN1626 (13.3%)
pN21172 (24.8%)
pN3393 (8.3%)
pN4226 (4.8%)
Unknown68 (1.4%)
Total4722
Table Pathological findings of lymph node metastasis, pN (UICC 7th)
Table 24

Pathological findings of lymph node metastasis, pN (UICC 7th)

Lymph node metastasisCases (%)
pN02164 (45.8%)
pN1 (1-2)1265 (26.8%)
pN2 (3-6)790 (16.7%)
pN3 (7-)392 (8.3%)
Unknown111 (2.4%)
Total4722

Regional lymph nodes are different in JES 10th and UICC 7th

Data for Tables 23 and 24 were analyzed from different variables in the registration application (Tables 25, 26, 27)

Table Pathological findings of distant organ metastasis, pM (JES 10th)
Table 25

Pathological findings of distant organ metastasis, pM (JES 10th)

Distant metastasisCases (%)
pMX172 (3.6%)
pM04490 (95.1%)
pM160 (1.3%)
Total4722
Table Residual tumor
Table 26

Residual tumor

Residual tumorCases (%)
RX156 (3.3%)
R04160 (88.1%)
R1216 (4.6%)
R2190 (4.0%)
Total472
Table Causes of death
Table 27

Causes of death

Cause of deathCases (%)
Death due to recurrence1383 (71.5%)
Death due to other cancer101 (5.2%)
 Death due to other disease (with recurrence)46 (2.4%)
 Death due to other disease (without recurrence)244 (12.6%)
 Death due to other disease (recurrence unknown)19 (1.0%)
Operative deatha25 (1.3%)
Postoperative hospital deathb40 (2.1%)
Unknown77 (4.0%)
Total of death cases1935

Operative mortality rate: 0.52%

Hospital mortality rate: 2.35%

aOperative death means death within 30 days after operation in or out of hospital

bHospital death is defined as death during the same hospitalization, regardless of department at time of death

Figure Survival of patients who underwent esophagectomy
Fig. 7

Survival of patients who underwent esophagectomy

Figure Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)
Fig. 8

Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)

Figure Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)
Fig. 9

Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)

Figure Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)
Fig. 10

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)
Fig. 11

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)

Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)
Fig. 12

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)

Figure Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)
Fig. 13

Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)

Figure Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)
Fig. 14

Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)

Figure Survival of patients who underwent esophagectomy according to residual tumor (R)
Fig. 15

Survival of patients who underwent esophagectomy according to residual tumor (R)

I. Clinical factors of esophageal cancer patients treated in 2012

Institution-registered cases in 2012 (Total 316 institutions)

Patient Background

Tables 1, 2, 3, 4, 5, 6, 7, 8. Age and gender Primary treatment Tumor location E esophageal, G gastric Histologic types of biopsy specimens Depth of tumor invasion, cT (UICC TNM 7th) Lymph node metastasis, cN (UICC TNM 7th) Distant metastasis, cM (UICC TNM 7th) Clinical stage (UICC TNM 7th)

II. Results of endoscopically treated patients in 2012

Tables 9, 10, 11 and Figs. 1, 2, 3. Details of endoscopic treatment for curative intent EMR endoscopic mucosal resection, PDT photodynamic therapy, YAG yttrium aluminum garnet, MCT microwave coagulation therapy, ESD endoscopic submucosal dissection Complications of EMR/ESD Pathological depth of tumor invasion of EMR/ESD specimens Survival of patients treated with EMR/ESD Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion, pT (UICC TNM 7th) Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

III. Results in patients treated with chemotherapy and/or radiotherapy in 2012

Tables 12, 13 and Figs. 4, 5, 6. Dose of irradiation (non-surgically treated cases) Dose of irradiation (surgically treated cases) Survival of patients treated with chemotherapy and/or radiotherapy Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th) Survival of patients treated with radiotherapy alone according to clinical stage (UICC TNM 7th)

IV. Results in patients who underwent esophagectomy in 2012

Tables 14,15,16,17,18,19,20,21,2223,24,25,26,27, and Figs. 7, 8, 9, 10, 11, 12, 13, 14, 15. Treatment modalities of esophagectomy Tumor location Approaches to tumor resection Thoracic includes thoracotomy and thoracoscopic Abdominal includes laparotomy and laparoscopic Video-assisted surgery Fields of lymph node dissection according to the location of the tumor 65 (1.4%) C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes Reconstruction route Organs used for reconstruction Histological classification Pathological depth of tumor invasion, pT (JES 10th) Survival of patients who underwent esophagectomy Survival of patients who underwent esophagectomy according to clinical stage (JES 10th) Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th) Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th) Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th) Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th) Survival of patients who underwent esophagectomy according to pathological stage (JES 10th) Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th) Survival of patients who underwent esophagectomy according to residual tumor (R) Pathological grading of lymph node metastasis, pN (JES 10th) Pathological findings of lymph node metastasis, pN (UICC 7th) Regional lymph nodes are different in JES 10th and UICC 7th Data for Tables 23 and 24 were analyzed from different variables in the registration application (Tables 25, 26, 27) Pathological findings of distant organ metastasis, pM (JES 10th) Residual tumor Causes of death Operative mortality rate: 0.52% Hospital mortality rate: 2.35% aOperative death means death within 30 days after operation in or out of hospital bHospital death is defined as death during the same hospitalization, regardless of department at time of death
Institution
Ageo Central General Hospital
Aichi Cancer Center
Aichi Medical University Hospital
Aizawa Hospital
Akaishi Hospital
Akita Kouseiren Hiraga Hospital
Akita University Hospital
Aomori City Hospital
Arao Municipal Hospital
Asahikawa Medical College Hospital
Cancer Institute Hospital of JFCR
Chiba Cancer Center
Chiba Medical Center
Chiba University Hospital
Chibaken Saiseikai Narashino Hospital
Chigasaki Municipal Hospital
Dokkyo Medical University Hospital
Dokkyo Medical University Saitama Medical Center
Ehime University Hospital
Eiju General Hospital
Foundation for Detection of Early Gastric Carcinoma
Fuchu Hospital
Fujioka General Hospital
Fujisawa Shounandai Hospital
Fujita Health University Hospital
Fukui Prefectural Hospital
Fukui University Hospital
Fukui-ken Saiseikai Hospital
Fukuoka Dental College and Dental Hospital
Fukuoka Saiseikai General Hospital
Fukuoka University Chikushi Hospital
Fukuoka University Hospital
Fukuoka Wajiro Hospital
Fukushima Medical University Hospital
Fukuyama City Hospital
Fussa Hospital
Gifu Prefectural General Medical Center
Gifu University Hospital
Gunma Central General Hospital
Gunma Prefectural Cancer Center
Gunma University Hospital
Gunmaken Saiseikai Maebashi Hospital
Hachinohe City Hospital
Hakodate Goryokaku Hospital
Hakodate National Hospital
Hamamatsu University School of Medicine, University Hospital
Heartlife Hospital
Higashiosaka City Medical Center
Hino Memorial Hospital
Hino Municipal Hospital
Hiratsuka City Hospital
Hiratsuka Kyosai Hospital
Hirosaki University Hospital
Hiroshima City Asa Hospital
Hiroshima City Hiroshima Citizens Hospital
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Hiroshima University Hospital
Hitachi General Hospital
Hokkaido University Hospital
Hyogo Cancer Center
Hyogo Prefectural Nishinomiya Hospital
Ibaraki Prefectural Central Hospital
Iizuka Hospital
Imazu Surgical Clinic
Inazawa City Hospital
International University of Health and Welfare Hospital
International Goodwill Hospital
International University of Health and Welfare Mita Hospital
Isehara Kyodo Hospital
Ishikawa Prefectural Central Hospital
Iwate Medical University Hospital
Iwate Prefectural Central Hospital
Iwate Prefectural Chubu Hospital
Iwate Prefectural Isawa Hospital
Japanese Red Cross Fukui Hospital
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Kyoto Daini Hospital
Japanese Red Cross Nagaoka Hospital
Japanese Red Cross Okayama Hospital
Japanese Red Cross Society Kyoto Daiichi Hospital
Japanese Red Cross Tottori Hospital
JCHO Kurume General Hospital
JCHO Kyushu Hospital
JCHO Miyazaki Konan Hospital
JCHO Osaka Hospital
JCHO Saitama Medical Center
JCHO Tokuyama Central Hospital
JCHO Yokohama Chuo Hospital
Jichi Medical University Hospital
Jichi Medical University Saitama Medical Center
Juntendo University Hospital
Juntendo University Shizuoka Hospital
Junwakai Memorial Hospital
Kagawa Prefectural Central Hospital
Kagawa Rosai Hospital
Kagawa University Hospital
Kagoshima Kenritsu Satsunan Hospital
Kagoshima University Hospital
Kaizuka City Hospital
Kameda General Hospital
Kanagawa Cancer Center
Kanazawa University Hospital
Kansai Medical University Hospital
Kansai Medical University Medical Center
Kansai Rosai Hospital
Kasamatsu Hospital
Kashiwa Kousei General Hospital
Kawakita General Hospital
Kawasaki Medical School Hospital
Kawasaki Medical School Kawasaki Hospital
Kawasaki Municipal Ida Hospital
Keio University Hospital
Keiyukai Sapporo Hospital
Kikuna Memorial Hospital
Kin-ikyo Chuo Hospital
Kinki Central Hospital
Kinki University Hospital
Kiryu Kosei General Hospital
Kishiwada City Hospital
Kitaakita Municipal Hospital
Kitakyushu Municipal Medical Center
Kitano Hospital
Kitasato Institute Hospital
Kitasato University Hospital
Kobe City Medical Center General Hospital
Kobe City Nishi-Kobe Medical Center
Kobe University Hospital
Kochi Health Sciences Center
Kochi University Hospital
Kokura Memorial Hospital
Kumagaya General Hospital
Kumamoto City Hospital
Kumamoto University Hospital
Kurashiki Central Hospital
Kurume University Hospital
Kusatsu General Hospital
Kyorin University Hospital
Kyoto University Hospital
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers
Kyushu Medical Center
Kyushu University Beppu Hospital
Kyushu University Hospital
Machida Municipal Hospital
Matsuda Hospital
Matsudo City Hospital
Matsushita Memorial Hospital
Matsuyama Red Cross Hospital
Mie University Hospital
Minamiosaka Hospital
Minamiyamato Hospital
Mino City Hospital
Mito Red Cross Hospital
Mitsui Memorial Hospital
Moriguchi Keijinkai Hospital
Murakami General Hospital
Musashino Red Cross Hospital
Nagahama City Hospital
Nagano Red Cross Hospital
Nagaoka Chuo General Hospital
Nagasaki University Hospital
Nagoya City East Medical Center
Nagoya City University Hospital
Nagoya City West Medical Center
Nagoya Daiichi Red Cross Hospital
Nagoya University Hospital
Nanpuh Hospital
Nara City Hospital
Nara Medical University Hospital
National Cancer Center Hospital
National Cancer Center Hospital East
National Defense Medical College Hospital
National Institute of Radiological Sciences Hospital
Nerima Hikarigaoka Hospital
NHO Beppu Medical Center
NHO Chiba Medical Center
NHO Chiba-East-Hospital
NHO Fukuoka-higashi Medical Center
NHO Himeji Medical Center
NHO Hokkaido Cancer Center
NHO Kanmon Medical Center
NHO Kure Medical Center
NHO Kyoto Medical Center
NHO Kyushu Cancer Center
NHO Matsumoto Medical Center
NHO Nagasaki Medical Center.
NHO Nagoya Medical Center
NHO Okayama Medical Center
NHO Osaka National Hospital
NHO Tokyo Medical Center
Nihonkai General Hospital
Niigata Cancer Center Hospital
Niigata City General Hospital
Niigata Prefectural Shibata Hospital
Niigata University Medical and Dental Hospital
Nikko Memorial Hospital
Nippon Medical School Chiba Hokusoh Hospital
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
Nippon Medical School Tama Nagayama Hospital
Nishinomiya Municipal Central Hospital
NTT Medical Center Tokyo
NTT WEST Osaka Hospital
Numazu City Hospital
Obihiro Kousei Hospital
Ogachi Central Hospital
Ogaki Municipal Hospital
Ohta Nishinouchi Hospital
Oita Red Cross Hospital
Oita University Hospital
Okayama Saiseikai General Hospital
Okayama University Hospital
Omuta Tenryo Hospital
Osaka City General Hospital
Osaka City University Hospital
Osaka Ekisaikai Hospital
Osaka General Medical Center
Osaka International Cancer Institute
Osaka Medical College Hospital
Osaka Police Hospital
Osaka Red Cross Hospital
Osaka University Hospital
Otsu City Hospital
Rinku General Medical Center
Ryukyu University Hospital
Saga University Hospital
Saga-ken Medical Center Koseikan
Saiseikai Fukushima General Hospital
Saiseikai Kyoto Hospital
Saiseikai Utsunomiya Hospital
Saiseikai Yahata General Hospital
Saiseikai Yokohamashi Tobu Hospital
Saitama Cancer Center
Saitama City Hospital
Saitama Medical University Hospital
Saitama Medical University International Medical Center
Saitama Medical University Saitama Medical Center
Sakai City Medical Center
Saku Central Hospital
Sanin Rosai Hospital
Sendai City Hospital
Sendai Medical Center
Shiga General Hospital
Shiga University of Medical Science Hospital
Shikoku Cancer Center
Shimane University Hospital
Shimizu Welfare Hospital
Shinko Hospital
Shizuoka Cancer Center
Shizuoka City Shizuoka Hospital
Shizuoka General Hospital
Showa University Hospital
Showa University Koto-Toyosu Hospital
Sonoda Daiichi Hospital
Southern Tohoku General Hospital
St. Luke’s International Hospital
St. Marianna University School of Medical Hospital
Steel Memorial Hirohata Hospital
Sugita Genpaku Memorial Obama Municipal Hospital
Suita Municipal Hospital
Tachikawa Hospital
Takasago Municipal Hospital
Teikyo University Chiba Medical Center
Teikyo University Hospital
Teine Keijinkai Hospital
Tenri Hospital
The Jikei University Daisan Hospital
The Jikei University Hospital
Tochigi Cancer Center
Toho University Ohashi Medical Center
Toho University Omori Medical Center
Toho University Sakura Medical Center
Tohoku University Hospital
Tokai University Hachioji Hospital
Tokai University Hospital
Tokai University Tokyo Hospital
Tokushima Red Cross Hospital
Tokushima University Hospital
Tokyo Dental College Ichikawa General Hospital
Tokyo Medical and Dental University Hospital
Tokyo Medical University Hachioji Medical Center
Tokyo Medical University Hospital
Tokyo Medical University Ibaraki Medical Center
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo Metropolitan Tama Medical Center
Tokyo Saiseikai Central Hospital
Tokyo University Hospital
Tokyo Women’s Medical University Hospital
Tokyo Women’s Medical University Medical Center East
Tokyo Women’s Medical University Yachiyo Medical Center
Tonan Hospital
Toranomon Hospital
Toshima Hospital
Tottori Prefectural Central Hospital
Tottori University Hospital
Toyama Prefectural Central Hospital
Toyama University Hospital
Toyonaka Municipal Hospital
Tsuchiura Kyodo Hospital
Tsukuba University Hospital
Tsuruoka Municipal Shonai Hospital
University Hospital, Kyoto Prefectural University of Medicine
University of Miyazaki Hospital
Urasoe General Hospital
Wakayama Medical University Hospital
Yamagata Prefectural Central Hospital
Yamagata Prefectural Shinjo Hospital
Yamagata University Hospital
Yamaguchi University Hospital
Yamaguchi-ken Saiseikai Shimonoseki General Hospital
Yamanashi Prefectural Central Hospital
Yamanashi University Hospital
Yao Municipal Hospital
Yokohama City Municipal Hospital
Yokohama City University Medical Center
Yokohama Rosai Hospital
Yuri Kumiai General Hospital

(Total 316 institutions)

  33 in total

1.  Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation.

Authors:  Kosuke Nomura; Toshiro Iizuka; Daisuke Kaji; Yuki Asano-Mori; Yorinari Ochiai; Yugo Suzuki; Junnosuke Hayasaka; Satoshi Yamashita; Akira Matsui; Daisuke Kikuchi; Shuichi Taniguchi; Yutaka Takazawa; Shu Hoteya
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 2.  Endoscopic resection for gastrointestinal tumors (esophageal, gastric, colorectal tumors): Japanese standard and future prospects.

Authors:  Yuka Yanai; Chizu Yokoi; Kazuhiro Watanabe; Naoki Akazawa; Junichi Akiyama
Journal:  Glob Health Med       Date:  2021-12-31

3.  Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.

Authors:  Seiichiro Mitani; Ken Kato; Hiroyuki Daiko; Yoshinori Ito; Isao Nozaki; Takashi Kojima; Masahiko Yano; Satoru Nakagawa; Masaki Ueno; Masaya Watanabe; Shigeru Tsunoda; Tetsuya Abe; Shigenori Kadowaki; Tomohiro Kadota; Keita Sasaki; Ryunosuke Machida; Yuko Kitagawa
Journal:  J Gastroenterol       Date:  2022-05-11       Impact factor: 6.772

4.  Association between body mass index and oesophageal cancer mortality: a pooled analysis of prospective cohort studies with >800 000 individuals in the Asia Cohort Consortium.

Authors:  Sangjun Lee; Jieun Jang; Sarah Krull Abe; Shafiur Rahman; Eiko Saito; Rashedul Islam; Prakash C Gupta; Norie Sawada; Akiko Tamakoshi; Xiao-Ou Shu; Woon-Puay Koh; Atsuko Sadakane; Ichiro Tsuji; Jeongseon Kim; Isao Oze; Chisato Nagata; San-Lin You; Myung-Hee Shin; Mangesh S Pednekar; Shoichiro Tsugane; Hui Cai; Jian-Min Yuan; Wanqing Wen; Kotaro Ozasa; Sanae Matsuyama; Seiki Kanemura; Aesun Shin; Hidemi Ito; Keiko Wada; Yumi Sugawara; Chien-Jen Chen; Yoon-Ok Ahn; Yu Chen; Habibul Ahsan; Paolo Boffetta; Kee Seng Chia; Keitaro Matsuo; You-Lin Qiao; Nathaniel Rothman; Wei Zheng; Manami Inoue; Daehee Kang; Sue K Park
Journal:  Int J Epidemiol       Date:  2022-08-10       Impact factor: 9.685

5.  Perioperative Predictive Markers for Recurrence of Esophageal Cancer after Esophagectomy.

Authors:  Yoshinori Fujiwara; Masaharu Higashida; Hisako Kubota; Yuko Okamoto; Shumei Mineta; Shunji Endo; Tomio Ueno
Journal:  Gastrointest Tumors       Date:  2021-03-17

6.  Salvage Photodynamic Therapy Using Talaporfin Sodium for Local Failure of Esophageal Squamous Cell Carcinoma.

Authors:  Yuichiro Ikebuchi; Akira Yoshida; Hiroki Kurumi; Yu Kamitani; Sho Yasui; Yusuke Nakada; Koichiro Kawaguchi; Kazuo Yashima; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2021-02-22       Impact factor: 1.641

7.  Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.

Authors:  Chen Li; Lijun Tan; Xiao Liu; Xin Wang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Nan Bi; Lei Deng; Wenqing Wang; Tao Zhang; Wenjie Ni; Xiao Chang; Weiming Han; Linrui Gao; Shijia Wang; Zefen Xiao
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

8.  Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Authors:  Ryujiro Akaishi; Fumiyoshi Fujishima; Hirotaka Ishida; Junichi Tsunokake; Takuro Yamauchi; Yusuke Gokon; Shunsuke Ueki; Toshiaki Fukutomi; Hiroshi Okamoto; Kai Takaya; Chiaki Sato; Yusuke Taniyama; Tomohiro Nakamura; Naoki Nakaya; Takashi Kamei; Hironobu Sasano
Journal:  Esophagus       Date:  2022-01-08       Impact factor: 3.671

Review 9.  Non-Acid Fluid Exposure and Esophageal Squamous Cell Carcinoma.

Authors:  Ali Soroush; Arash Etemadi; Julian A Abrams
Journal:  Dig Dis Sci       Date:  2021-07-08       Impact factor: 3.487

10.  Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907.

Authors:  Hiroki Hara; Junki Mizusawa; Shuichi Hironaka; Ken Kato; Hiroyuki Daiko; Tetsuya Abe; Kenichi Nakamura; Nobutoshi Ando; Yuko Kitagawa
Journal:  Esophagus       Date:  2020-06-08       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.